Genelabs begins Hep E Phase II

GNLB said that licensee GlaxoSmithKline (GSK; LSE:GSK) began a Phase II trial in Nepal of a vaccine to prevent hepatitis E virus infection. The study has enrolled about 2,000 healthy volunteers, who w...